In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Teva set to invest in MediWound:

This article was originally published in Clinica

Executive Summary

Israeli wound care company MediWound has attracted funding from several institutional, private and corporate investors including Teva Pharmaceutical Industries, one of the world's largest generic pharmaceutical companies, which is set to invest $15m. Teva will pay $10m for shares from MediWound stockholders and an additional $5m for shares issued by the company itself. The transaction will also see Teva gain exclusive marketing and distribution rights to MediWound's Debrase gel dressing for burns in certain countries, while MediWound will manufacture the product and supply it to Teva for commercialisation. Petach Tikva-based Teva will have an option to extend the licence agreement to include Europe and North America. Debrase, currently in phase III clinical trials, can remove 90% of burnt tissue on a patient within four hours, according to MediWound.

You may also be interested in...

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.

FDA Wants To Put Hep C Tests On 510(k) Pathway

The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts